Immunomedics,Inc. (NASDAQ:IMMU) Files An 8-K Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.

Immunomedics,Inc. (the Company) published an investor
presentation, which will be available on the Companys website,
www.immunomedics.com, and is included as Exhibit99.1 to this
report and incorporated herein by reference. The Company is not
undertaking to update this presentation. This report should not
be deemed an admission as to the materiality of any information
contained in the investor presentation.

The information in Item 7.01 of this Current Report on Form8-K,
including Exhibit99.1 hereto, is being furnished and shall not be
deemed to be filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing made by the
Company under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.

Item 9.01Financial Statements and
Exhibits.

(d)Exhibits.

About Immunomedics, Inc. (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information

Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session up +0.21 at 3.90 with 2,678,536 shares trading hands.